The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | The role of CAR-T therapy for lymphoma in 2024: expert session highlights
In this video, Sridhar Chaganti, MD, PhD, MRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, gives an overview of a session held at this year’s EBMT Meeting which focused on the role of CAR-T therapy for patients with lymphoma. Dr Chaganti highlights currently approved agents including axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), which can be employed for patients with relapsed diffuse large B-cell lymphoma (DLBCL). Commenting on patient eligibility, Dr Chaganti emphasizes the importance of investigating the efficacy of CAR-T therapy in older patients, highlighting the ALYCANTE (NCT04531046) and PILOT (NCT03483103) studies. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
